|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
US5834428A
(en)
*
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
EP2218734B1
(en)
|
1996-04-12 |
2013-06-05 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
|
US20020025933A1
(en)
*
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
|
CA2236519C
(en)
*
|
1997-05-02 |
2011-09-13 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
|
SE9802080D0
(sv)
*
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
CZ295890B6
(cs)
|
1998-12-07 |
2005-11-16 |
Societe De Conseils De Recherches Et D'application |
Analogy GLP-1, mající kyselinu aminoizomáselnou pozici 8 a D-arginin na pozici 36, jejich použití a farmaceutické prostředky je obsahující
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
|
JP5161412B2
(ja)
|
2000-09-18 |
2013-03-13 |
サノス・バイオサイエンス・アクティーゼルスカブ |
Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
|
|
EP1360202B1
(en)
*
|
2001-02-16 |
2008-05-21 |
ConjuChem Biotechnologies Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
|
WO2004035624A2
(en)
*
|
2002-10-14 |
2004-04-29 |
Novo Nordisk A/S |
Glucagon - like peptide - 2 variants
|
|
ATE502665T1
(de)
|
2003-02-04 |
2011-04-15 |
Novo Nordisk As |
Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
|
|
EP1608680A2
(en)
*
|
2003-03-24 |
2005-12-28 |
Novo Nordisk A/S |
Glp-2 derivatives
|
|
ATE549028T1
(de)
*
|
2003-05-15 |
2012-03-15 |
Tufts College |
Stabile analoga von glp-1
|
|
EP1711523B1
(en)
|
2003-12-16 |
2012-10-10 |
Ipsen Pharma |
Analogues of glp-1
|
|
ES2397241T3
(es)
|
2004-01-21 |
2013-03-05 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
|
ES2427150T3
(es)
|
2004-11-01 |
2013-10-29 |
Nps Pharmaceuticals, Inc. |
Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
|
|
CN102659938B
(zh)
*
|
2005-05-04 |
2016-01-20 |
西兰制药公司 |
胰高血糖素样肽-2（glp-2）类似物
|
|
US7498141B2
(en)
|
2005-12-01 |
2009-03-03 |
Nps Pharmaceuticals, Inc. |
Assay system for GLP-2 receptor ligands
|
|
BRPI0718566A2
(pt)
|
2006-11-08 |
2014-03-11 |
Zealand Pharma As |
Peptídeo, análogo do mesmo, composição farmacêutica, usos de um análogo de peptídeo, e de uma molécula de ácido nucléico, de um vetor de expressão, ou de uma célula hospedeira, molécula de ácido nucléico, vetor de expressão, célula hospedeira, métodos para produzir o análogo de peptídeo-2 tipo-glucagon (glp-2), e, kit terapêutico.
|
|
EP2314616A1
(en)
*
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
CN103429742A
(zh)
|
2010-10-15 |
2013-12-04 |
康奈尔大学 |
用于治疗内分泌、胃肠或自体免疫性疾病的组合物和方法
|
|
CN102924589B
(zh)
*
|
2011-08-11 |
2016-08-24 |
中肽生化有限公司 |
胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
|
|
DK2755675T3
(en)
|
2011-09-12 |
2018-08-06 |
Amunix Operating Inc |
Glucagon-like peptide-2 compositions and methods for their preparation and use
|
|
CN107496932A
(zh)
|
2012-02-27 |
2017-12-22 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
|
SG11201903938XA
(en)
|
2016-12-09 |
2019-05-30 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
|
DK3638291T3
(da)
|
2017-06-16 |
2021-10-18 |
Zealand Pharma As |
Dosisregimer til indgivelse af glucagon-lignende-peptid-2 (GLP-2)-analoger
|
|
WO2020020904A1
(en)
|
2018-07-23 |
2020-01-30 |
Zealand Pharma A/S |
Therapeutic uses of glp-2 agonists
|